Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Diversity & Inclusion Innovation

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

  • Opinion

Executive Summary

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

You may also be interested in...



How Little Moderna Made Big Waves In Trial Diversity

Early on, the company committed to transparency while making sure its Phase III vaccine study enrolled a population reflective of the US as a whole. Moderna talks to Scrip about the experience.

Publisher's Spotlight: Entry Reminder For The Citeline Awards

The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more. 

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Diversity & Inclusion Innovation
Latest Headlines

Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies

See All
UsernamePublicRestriction

Register

SC146216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By